In keeping with previous findings, the latest study on a new genetic test confirms that it can predict whether melanomas will spread. These results were presented at the American Academy of Dermatology meeting. While survival rates are generally high for people with melanomas that have not yet spread, metastases do occur in about 14% of this group. The test, called DecisionDx-Melanoma, classifies people as either low or high risk of metastasis based on the activity of 31 genes in their tumors. To date, the test has been validated using follow-up data on 400 people with early-stage melanomas. Knowing which people are likely to develop melanoma tumors in other parts of their bodies will help doctors tailor their long-term care appropriately.